Navigation LinksBiology NewsHealth NewsBiology TechnologyMedicine Technology


We're sorry, that page (http://www.bio-medicine.org/medicine-news-1/sundia-meditech-appoints-dr--chen-chen-as-senior-vp-of-chemistry-50700-2/;msg90356) was not found.

Search medicine news 1 sundia meditech appoints dr chen chen as senior vp of chemistry 50700 2 ;msg90356 at Google

Search medicine news 1 sundia meditech appoints dr chen chen as senior vp of chemistry 50700 2 ;msg90356 at Yahoo

Search medicine news 1 sundia meditech appoints dr chen chen as senior vp of chemistry 50700 2 ;msg90356 at Msn

Google
 
(Date:11/5/2009)...rsity have developed synthetic molecules capable o...HIV-infected cells, as well as to prostate cancer ...urnal of the American Chemical Society , could lea...es. , The molecules called "antibody-recruitin...cruiting molecule targeting prostate cancer" (ARM-...
(Date:11/4/2009)...Long Beach and Riverside are responsible for a sig...a, and the true impact of air pollution and ship e...ated, according to researchers at the University o... appears in an online edition of the American Jou...t of all childhood asthma cases in Long Beach and ...
(Date:11/4/2009)...received more than $10 million in research grants ...stimulus program, bringing thetotal amount of stim...lion. Thirty-three projects achieved stimulus fun...er. , "The university has thoughtfully undertake...rly excellence to federal agency priorities. Thro...
Breaking Biology News(10 mins):New synthetic molecules trigger immune response to HIV and prostate cancer 2USC study finds big air pollution impacts on local communities 2OU achieves $10 million in stimulus grants for 33 projects on the Norman campus 2OU achieves $10 million in stimulus grants for 33 projects on the Norman campus 3Abbotts TRILIPIX 28R 29 28Fenofibric Acid 29 in Combination With Rosuvastatin Calcium Helps Patients With Mixed Dyslipidemia and Type 2 Diabetes Meet 48164 1Abbotts TRILIPIX 28R 29 28Fenofibric Acid 29 in Combination With Rosuvastatin Calcium Helps Patients With Mixed Dyslipidemia and Type 2 Diabetes Meet 48164 2Abbotts TRILIPIX 28R 29 28Fenofibric Acid 29 in Combination With Rosuvastatin Calcium Helps Patients With Mixed Dyslipidemia and Type 2 Diabetes Meet 48164 3Abbotts TRILIPIX 28R 29 28Fenofibric Acid 29 in Combination With Rosuvastatin Calcium Helps Patients With Mixed Dyslipidemia and Type 2 Diabetes Meet 48164 4Cadient Group Brings Home the Gold and Two Bronze Aster Awards 12521 1Cadient Group Brings Home the Gold and Two Bronze Aster Awards 12521 2RiskMetrics Recommends That Providence Service Corporation Stockholders Vote for Providences Director Nominees on the White Proxy Card 48161 1RiskMetrics Recommends That Providence Service Corporation Stockholders Vote for Providences Director Nominees on the White Proxy Card 48161 2RiskMetrics Recommends That Providence Service Corporation Stockholders Vote for Providences Director Nominees on the White Proxy Card 48161 3RiskMetrics Recommends That Providence Service Corporation Stockholders Vote for Providences Director Nominees on the White Proxy Card 48161 4RiskMetrics Recommends That Providence Service Corporation Stockholders Vote for Providences Director Nominees on the White Proxy Card 48161 5RiskMetrics Recommends That Providence Service Corporation Stockholders Vote for Providences Director Nominees on the White Proxy Card 48161 6
(Date:11/9/2009)...tCall/ - Hard To Treat Diseases (HTDS.PK) www.htd...$41 billion international healthcare company, is a...r, Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd.,...begin a five-year, $1 billion China initiative wit... its investment in its China R&D facility, and...
(Date:11/9/2009)...late when it comes to preventing or improving a di...ke Off Pounds Sensibly), the nonprofit weight-loss...(Vocus) November 9, 2009 -- Tomorrow may be too la...etes condition, according to TOPS Club, Inc. (Take...upport organization., , ,Diabetes is a disease in ...
(Date:11/9/2009)... positive influence of sports participation on bon...Vocus) November 9, 2009 -- As people age fractures...ch has highlighted the importance of exercise and ...However, a new study published in the November/Dec... Approach reveals that there may be significant g...
(Date:11/9/2009).../ -- Actress Mariska Hargitay and the Joyful Hea...to raise awareness about the need for domestic vio...ilding healing and wellness kits for women in cris... to each of the estimated 600 women currently bein...iolence shelters. ,, "Our goal is to shine a li...
(Date:11/9/2009)...assador ,, WHITE PLAINS, N.Y., Nov. 9 /PRNews..., was born so early and with so many underdevelope...ld survive -- or if he would ever walk, talk, see ...Dimes 2010 National Ambassador. ,, Joshua,s mo...motherhood and I was completely devastated. My hus...
Breaking Medicine News(10 mins):Health News:Novartis to Acquire Majority Stake in Hard to Treat Diseases' (HTDS.PK) China Subsidiary H1N1 Vaccine Partner for US$125 Million 2Health News:Novartis to Acquire Majority Stake in Hard to Treat Diseases' (HTDS.PK) China Subsidiary H1N1 Vaccine Partner for US$125 Million 3Health News:Novartis to Acquire Majority Stake in Hard to Treat Diseases' (HTDS.PK) China Subsidiary H1N1 Vaccine Partner for US$125 Million 4Health News:Diabetes Prevention Is the Best Remedy, TOPS Medical Expert Says 2Health News:Diabetes Prevention Is the Best Remedy, TOPS Medical Expert Says 3Health News:High Impact Sports Participation May Improve Bone Mineral Density in Mature Athletes 2Health News:Actress Mariska Hargitay and the Joyful Heart Foundation Join philosophy to Serve Women in Crisis Throughout Los Angeles County 2Health News:Actress Mariska Hargitay and the Joyful Heart Foundation Join philosophy to Serve Women in Crisis Throughout Los Angeles County 3Health News:Six-Year-Old Survivor Fights for Preemies Like Himself 2Health News:Six-Year-Old Survivor Fights for Preemies Like Himself 3
BD BaculoGoldTM Transfection Kit 5 transfections from BD Biosciences Pharmingen
Sf9 Insect Cells from BD Biosciences Pharmingen
UltraClean Plant DNA Isolation Kit from Mo Bio Laboratories, Inc.
Propidium iodide from Research Organics, Inc.
Biology Products:
XKnife
Primus Linear Accelerator
Clinac 21EX Platinum
...en and reliable system. Varian accelerators offers...astest beam-on times to full stability and flatnes...m control for dynamic treatments, highest beam sta...LC) products that achieve the finest dose contouri...
Medicine Products:
(Date:11/9/2009)...,, SCHIEDLBERG, Austria, November 9 /PRNews...er the world have been working on the development ...ect communication channel,between the brain and a ...ed,patients to communicate or to control devices i...g the last years some patients have been supervise...
(Date:11/9/2009)... Product release is a res... subjects, research facilities and research safety...ion. , Cedar Knolls, NJ (...announced today that it has unveiled Pristima&trad...for research facilities that track the use and car...
(Date:11/6/2009)...,, TORONTO, Nov. 6 /PRNewswire-FirstCall/ - Mic...day that it has re-filed the Form 52-109F1 Certifi...ief Executive Officer and James Long, the Chief Fi...ed January 12, 2009 in connection with the annual ...ptember 30, 2008. ,, The Company initially file...
(Date:11/6/2009)...,, SAN MATEO, Calif., Nov. 6 /PRNewswire-FirstC..., Completed transfer of Qutenza(TM) E.U. Marketin...ade significant progress in commercial readiness a...Sales; Senior Director, Marketing; and Director, C...n to board as director and Audit Committee chairma...
Breaking Biology Technology:intendiX - Communication by Thoughts: First Patient-Ready System on the Market 2Xybion Unveils Pristima™ VM, an Integrated Enterprise Software Solution for Vivarium and Veterinary Care Management 2NeurogesX Reports Third Quarter 2009 Results 2NeurogesX Reports Third Quarter 2009 Results 3NeurogesX Reports Third Quarter 2009 Results 4NeurogesX Reports Third Quarter 2009 Results 5NeurogesX Reports Third Quarter 2009 Results 6NeurogesX Reports Third Quarter 2009 Results 7NeurogesX Reports Third Quarter 2009 Results 8NeurogesX Reports Third Quarter 2009 Results 9NeurogesX Reports Third Quarter 2009 Results 10
(Date:11/9/2009)... BEND, Oregon, November 9 Bend...of experience in applying innovative pharmaceutica...fficult scientific and,technical problems, announc...with Vertex Pharmaceuticals Incorporated, a global... MA. , Through this new collaboration, Ve...
(Date:11/9/2009)... BOSTON, Nov. 9 PAREXEL ...ing global biopharmaceutical services provider, to...ety capabilities for early phase clinical developm...nc., which manufactures and distributes electrocar...wide. PAREXEL is using Mortara Instrument,s Survey...
(Date:11/9/2009)... HOPKINTON, Mass., Nov. 9 /PRNewswire-FirstCall/ -...leading provider of tools and services for drug di...d that its Caliper Discovery Alliances and Service...tment for $1.8 million under its contract with the...,s ToxCast screening program. This new task order...
Breaking Medicine Technology:Bend Research and Vertex Pharmaceuticals Enter New Scientific Collaboration 2Bend Research and Vertex Pharmaceuticals Enter New Scientific Collaboration 3PAREXEL Enhances Early Phase Cardiac Safety Capabilities Through Alliance With Mortara Instrument 2PAREXEL Enhances Early Phase Cardiac Safety Capabilities Through Alliance With Mortara Instrument 3PAREXEL Enhances Early Phase Cardiac Safety Capabilities Through Alliance With Mortara Instrument 4PAREXEL Enhances Early Phase Cardiac Safety Capabilities Through Alliance With Mortara Instrument 5Caliper Awarded New Task Order for EPA ToxCast Program 2Caliper Awarded New Task Order for EPA ToxCast Program 3CyberKnife Center of Miami Executive Director James G Schwade M D Garners Ultimate Miami CEO Award 48158 1Gentiva 28R 29 Health Services to Present at Jefferies 3rd Annual Healthcare Conference 48155 1Gentiva 28R 29 Health Services to Present at Jefferies 3rd Annual Healthcare Conference 48155 2Gentiva 28R 29 Health Services to Present at Jefferies 3rd Annual Healthcare Conference 48155 3PDL BioPharma Provides Second Quarter 2009 Revenue Guidance of Approximately 24125 Million 12517 1PDL BioPharma Provides Second Quarter 2009 Revenue Guidance of Approximately 24125 Million 12517 2PDL BioPharma Provides Second Quarter 2009 Revenue Guidance of Approximately 24125 Million 12517 3